



## I PRESERVE TRIAL

### Irbesartan in Heart Failure with Preserved EF

**BACKGROUND:** Approximately 50% of HF pts have preserved EF ( $\geq 45\%$ ) (HFPEF). HFPEF primarily affects women and the elderly & is frequently associated hypertension.

**PURPOSE:** To determine whether treatment with the ARB Irbesartan reduces mortality & morbidity in HFPEF pts.

**DESIGN:** Randomized, double-blind, placebo-controlled trial of 4,128 pts with follow-up till 1,440 primary endpoints occurred.

**Primary Endpoint:** All cause mortality & protocol-specified CV hospitalizations (for HF, MI, stroke, arrhythmia).

**Secondary Endpoints:**

- HF death or hospitalization
- QOL (Minnesota)
- Death, MI or stroke
- CV death

### RESULTS:

All cause mortality & CV Hosp: HR (95% CI = 0.95 (0.86 – 1.05) p = 0.35

CV Mortality: HR (95% CI = 1.02 (0.87 – 1.19) p = 0.85

HF Death or Hospitalization: HR (95% CI = 1.01 (0.88 – 1.16) p = 0.89

**Conclusion:** Irbesartan was safe & well tolerated but did not meet its primary & secondary endpoints.